Skip to Main Content
FREE SHIPPING IN USA ON ORDERS OVER $75
Shopping Cart

Melatonin

Melatonin has long been known to aid in sleep; however, a myriad of other benefits has been discovered in the last decade of research. During this time, the therapeutic and physiological dose of melatonin for various uses has been explored, as has the form used in supplements. Melatonin, as a dietary supplement, comes in a variety of dosages from as low as 0.3mg to as high as 20mg. Historically, it was extracted from the pineal glands of animals, most often from cow or pig sources. Presently however, it is almost exclusively synthetically produced. Plants naturally contain melatonin but at extremely low levels, (nanograms per milligram) making it very difficult to extract a sufficient amount of melatonin for therapeutic doses. However, more recently there has been one plant-based melatonin product developed which is now commercially available with levels of 1mg of melatonin per 100mg of herbal biomass. Melatonin comes in immediate-release form or sustained-release, also referred to as slow-, controlled-, or time-release. Sustained-release appears to have less hypnotic or drowsiness effects than the immediate release and the benefits appear to be equal to or greater than the immediate-release form relative to primary insomnia; sleeplessness not attributed to a medical condition or medication.

Melatonin is a naturally occurring hormone produced in the human body by the pineal gland and secreted into the bloodstream. On average, the pineal gland produces between 0.1mg and 0.8mg of melatonin per day. Children typically produce double the amount of melatonin (0.5mg - 0.8mg) compared to adults. Production gradually declines as people age, starting in the late twenties through to the fifties, with production leveling out at approximately 0.3mg. However, production can drop even further due to diet and other lifestyle factors.1 People of all ages dealing with jet lag, shift work, or challenges to their circadian rhythm due to environment or seasonal changes may also be affected by low melatonin levels. Melatonin is produced in response to darkness, as perceived by the retina of the eye. It is reduced by exposure to light and artificial light may also contribute to the reduction of a person’s melatonin production and increased risk of disease. A number of conditions and medications have been shown to depress melatonin levels in the blood: Prostate cancer, breast cancer, autism, epilepsy, antidepressants, non-steroidal anti-inflammatory drugs (NSAIDS), beta-blockers, and calcium channel blockers for high blood pressure, caffeine, tobacco, and alcohol use have all been associated with low melatonin levels.

Benefits of Melatonin

Sleep

Melatonin and sleep studies have looked at how shift work, particularly night work, may increase the risk of cancer and may aggravate gastrointestinal and cardiovascular disease, complicate pregnancy, and interfere with drug therapy.2 Multiple studies, opinions, and guidelines have suggested melatonin as a primary therapeutic for improved health and sleep of shift workers.3,4,5 A meta-analysis of melatonin for the treatment of primary sleep disorders looked at 19 studies involving 1683 individuals. Melatonin had a statistically significant effect on reducing sleep latency and increasing total sleep time. Trials that used higher doses of melatonin and conducted over a longer duration demonstrated even greater effects on these two sleep issues, and overall sleep quality was also significantly improved in melatonin users.

A 2017 systematic review found 5,030 studies on melatonin and sleep, but only 12 were included as they were randomized, controlled and single or double-blind.

The summary concluded that melatonin is indicated for:

  • Insomnia
    • Immediate release 1-3mg, <30 mins before bed
    • Slow release can be used for sleep maintenance problems
  • Regulating sleep in blind individuals
    • Replicated normal endogenous pattern6
  • Delayed Sleep Phase

A delayed sleep phase is a persistent shift in sleep-wake times later than social norms, causing insomnia-like symptoms, difficulty waking in the morning, and excessive daytime sleepiness. This is best treated with melatonin at select times and a select amount of time prior to the desired bedtime and wake time. There are specific phase advancing protocols to support the sleep phase if current sleep times are less than three hours later than target time, and a different protocol if the need is to advance the phase when it is less than three hours. These protocols are best known by sleep specialists.7

Brain Health

Melatonin is an antioxidant, combating free radicals, which can cause oxidative damage to our cells. Melatonin can also cross the blood-brain barrier, making it one of the most potent antioxidants in the brain.8 Most substances, including antioxidants that we consume, do not cross this barrier. Yet, the wisdom of nature has provided us the ability to manufacture this defense mechanism and may in part explain its benefit in cognitive diseases.

In a small pilot study of elderly patients with mild cognitive deficit, the ability to remember previously learned items improved, along with a reduction in depression, with the use of melatonin.9 A larger longer-term study found patients with mild cognitive impairment scored better on the Mini Mental Status Exam and the Sleep Disorders Index when given melatonin.10 Oxidative stress is a leading cause in age-related brain dysfunction by impairing neurogenesis and researchers are diving into potential influences on monoamine synthesis which is a common target for diseases such as schizophrenia and Parkinsons.11,12 Additionally, research into melatonin and its anti-beta-amyloid aggregation effects are being studied. Beta-amyloid plaque is found in the brains of patients with Alzheimer’s disease and these mechanisms along with the symptomatic relief of cognitive impairment found in other studies make melatonin a possible solution.13

Neurodegenerative conditions share mitochondrial dysfunction in their pathogenesis. Mitochondria, being the cellular source of energy, are also the target of oxidative damage. The sensitive nature of mitochondrial membranes, which can be damaged by a plethora of factors, may find protection with oral administration of melatonin. Melatonin is selectively taken up by mitochondrial membranes, a function not shared by other antioxidants.14,15

Cardiovascular Health

Improvements in LDL cholesterol and blood pressure have been shown in as few as two months of melatonin use in patients with documented metabolic syndrome who had not responded to a three-month intervention of therapeutic lifestyle modifications.16 Further, it has been shown to decrease nocturnal hypertension, improve systolic and diastolic blood pressure, reduce the pulsatility index in the internal carotid artery, decrease platelet aggregation, and reduce serum catecholamine levels.17,18,19

More recent studies have shown melatonin improving outcomes in patients with heart failure and it is being considered as a preventive and adjunctive curative measure in these patients.20

Pregnancy and Fertility

A review of the available literature by obstetric researchers found that because pregnancy has increased oxygen demands on the body and thus more free radical damage, melatonin may be a critical consideration for both complicated and normal pregnancies, counter to the traditional stance of avoiding it during pregnancy. In fact, the use of melatonin during pregnancy, which has been found safe in both mother and fetus according to some research, could prove to help limit complications during the critical periods prior to and shortly after delivery.21

A recent study suggested that preeclampsia has a seasonal variation since it was observed that reduced melatonin levels were associated with the development of preeclampsia. Therefore, it has been suggested that melatonin may be helpful in having a successful pregnancy.22 Pregnancy is a critical time for fetal programming of hypertension. Melatonin, as an antioxidant therapy, can prevent
hypertension in offspring of patients with a family history of hypertension.23

It is hypothesized that oxidative stress has an adverse effect on fertility. Since melatonin is a strong scavenger of oxidative factors it could improve fertility.24,25 A review of the literature also suggests that melatonin improves sperm quality and oocyte quality, resulting in increased fertilization. Melatonin shows promise for advanced age infertility and improving IVF outcomes.26

Endometriosis

The antioxidant effects of melatonin also appear to alleviate the chronic pelvic pain of endometriosis. In this condition, endometrial tissue implants at various sites inside the body and causes inflammation. The pelvic pain experienced with endometriosis can be severe and surgical removal of the abnormally placed tissue can lead to problems of its own, such as adhesions that affect digestion and fertility. In a randomized double-blind placebo-controlled trial, Schwertner, et. al. found that melatonin at a higher dose of 10 mg nightly reduced endometriosis pain by about 40% and reduced the use of pain-relieving medications by 80% over 2 months.27 This nutrient alone is not enough to manage endometriosis, but when it comes to pain relief it’s a safer starting point than pharmaceutical analgesics which may have significant side effects.28 

Digestive Health

Broad therapeutic benefits also exist for melatonin’s role in oral care and digestive function, periodontal inflammation, post-dental surgery, and as antioxidant protection against dental materials.29,30 Studies have investigated its use in Helicobacter pylori infections, gastric and duodenal ulcers,31 gastroesophageal reflux disease (GERD), and irritable bowel syndrome.32 Melatonin and its precursor tryptophan have protective effects on mucosal tissue. Of interest is a study in which H. pylori-infected individuals were given melatonin, placebo, or tryptophan with omeprazole. Each of the three groups had seven subjects with gastric ulcers and seven with duodenal ulcers. At the 21-day mark, those treated with either tryptophan (250mg twice daily) or melatonin (5mg twice daily) had no ulcers, whereas the placebo group had three gastric ulcers and three duodenal ulcers. Also of note, is that in one study on GERD, melatonin given at 3mg daily over 8 weeks showed similar improvement in symptoms as omeprazole.33 

A recent study indicated that gut bacteria have their own circadian clock and respond to melatonin, allowing the bacteria to synchronize with the human circadian rhythm.34 Additionally, there is research showing that our gastrointestinal tract produces its own melatonin, which in turn supports normal gut motility, mucosal integrity via its antioxidant activity, and support of the microbiome.

Oxidative Stress, and Inflammation

In a study of oxidative stress markers in those who ran a 50 km (31 mile) course, those who took melatonin had reduced levels of stress markers, underscoring not only the mechanism of antioxidant protection, but also a practical use in athletes who are exposed to oxidative stress and inflammation that may increase their risk for vascular incidents.35 Because melatonin has been shown to inhibit NF-KB, an important cellular signaling agent which is induced by reactive oxygen species, chemical stressors, and radiation, we will likely see additional trials looking at anti-inflammatory conditions which may be helped by this mechanism.36 

Migraines and Headaches

Migraines are chronic and debilitating, affecting 12-20% of the world’s population, more commonly women. Women account for about 75% of the 28 million Americans who experience migraine headaches. A randomized, multi-center, parallel-group design was conducted in which melatonin was compared with amitriptyline and placebo for 12 weeks. A 3mg dose of melatonin reduced migraine frequency demonstrating the same effectiveness as amitriptyline in the primary endpoint of frequency of migraine headaches per month. Melatonin was superior to amitriptyline in the percentage of patients with a greater than 50% reduction in migraine frequency and melatonin was better tolerated than amitriptyline.37 It has also been reported as an effective treatment for primary headache disorders.38

Tinnitus

Melatonin has been used for the treatment of chronic tinnitus in adults. A significantly greater decrease in tinnitus scores on an audiometric test and self-rated tinnitus was observed after treatment with melatonin compared to placebo in one study.39 Hormonal influences such as puberty, the menstrual cycle, pregnancy, hormonal birth control, hormone replacement therapy, and menopause are possible explanations why women may experience tinnitus. Other changes that could influence and worsen tinnitus during these times could be lack of sleep, fatigue, and stress. Whatever the cause, the use of melatonin 3mg in the evening is a reasonable and safe supplement to consider in tinnitus.

Autism and ADHD

The profound effects of melatonin may be far-reaching. Research groups have evaluated the genes that encode for melatonin metabolism in patients with attention deficit hyperactivity disorder compared to controls. Genetic results suggest melatonin-signaling deficiency in ADHD.40

Sleep disturbances in autism have led researchers to investigate melatonin’s role in this spectrum of disorders as well. Considered to have a genetic component, it was found that autistic patients have low melatonin levels, caused by a primary deficit in ASMT gene activity.41 A review article found that patients with autism had improved sleep parameters, better daytime behavior, and minimal side effects with melatonin use.42

Immune Function

Melatonin has effects on the immune system, including some anti-carcinogenic properties. In 1991, Dr. Paolo Lissoni conducted a study on patients with metastatic solid tumors and demonstrated that high doses of melatonin were effective in arresting tumor growth and improving quality of life markers.43 His group, considered pioneers in this field, have provided several reports on this dose throughout the 1990’s with subsequent studies confirming his findings.

A study reported that melatonin is linked to the seasonal relapse rate in MS patients. The same research team also found that melatonin reduced immune-cell production of inflammatory immune messengers and increases anti-inflammatory messengers.44

Eye Health

Glaucoma may be the next therapeutic target for melatonin. Ophthalmic researchers are developing an understanding of how the potent antioxidant potential of melatonin may reduce intraocular pressure and the recognized comorbidities of depression, anxiety, and sleep disturbances.45 Age-related macular degeneration is another serious ophthalmic condition that could benefit from melatonin administration.46 

Jet Lag

As our world gets smaller, more individuals need to recover from jet lag sooner and faster. There are a number of studies supporting melatonin’s uses in reducing the ill effects of jet lag and speeding up the normalization of circadian rhythms.47

In a Cochrane review, 9 out of 10 trials found melatonin was effective in reducing jet lag symptoms in travelers, especially if travelling eastward or over greater than 5 time zones. See dosing recommendations in next section.48

Bone Health

Melatonin may also hold promise as a modulator of anabolic bone formation and metabolism, especially if used in combination with other bone nutrients such as Vitamins D and K. According to the MOTS trial, melatonin may be able to reverse bone loss.49 Melatonin is a hormone and nutritional supplement that has demonstrated efficacy to renormalize bone marker turnover in peri-menopausal women50 increase bone density in post-menopausal women with osteopenia.51

Dosing

Over the last decade we have learned that using the lowest effective dose of any hormone is the most appropriate course, and that larger doses do not always infer more benefits. Too much melatonin has been documented to produce side effects such as amnesia or a “melatonin hangover” the next day, finding it harder to fall asleep, or sleeping well for 3-4 hours and then waking up and not being able to go back to sleep. Some doctors also believe that high doses over the long-term can negatively impact the body’s own production of melatonin, with patients often becoming dependent over time. Doctors are also aware of patients reporting vivid dreams or even nightmares. Since the body produces between 0.1mg and 0.8mg of melatonin daily, doses in this range are known as physiologic doses. Amounts above this range are known as pharmacologic doses.

Much has been written about melatonin’s therapeutic value, but the doses used in studies appear to be chosen haphazardly or based on previous studies that did not have an explicit purpose for choosing the amount. Therefore, some dogma about dosing melatonin has developed in both the scientific research community and in clinical medicine. Researchers from the Massachusetts Institute of Technology in 2001 compared physiologic doses to pharmacologic doses and very low (below physiologic) doses and found the best objective data at 0.3mg of melatonin. Sleep data was obtained by polysomnography. The physiologic dose (0.3mg) restored sleep efficiency and elevated plasma melatonin levels to normal. The pharmacologic dose (3.0mg), like the lowest dose (0.1 mg), also improved sleep; however, it induced hypothermia and caused plasma melatonin to remain elevated into the daylight hours. Interestingly, the control group (not insomniacs) also had low melatonin levels but melatonin did not improve sleep. The low dose in the study did not raise melatonin levels into the normal range. It is fascinating that we need to lower our body temperature to sleep well but doing so excessively can disrupt sleep. Melatonin’s action of lowering body temperature is important to monitor and may give significant clues to the appropriate dosage. Symptoms like needing more blankets, or excessive movement, may suggest too much melatonin at night.

This same group evaluated the 0.3mg dose in children who suffer from Angelman’s Syndrome, a rare genetic condition in which sleep maintenance is difficult, among other developmental issues. Parents were asked to log sleep habits and 0.3mg was administered 30-60 minutes before bedtime. Subjects wore an actigraph which measured movements per minute during the night. Serum levels of melatonin were measured hourly over two different 21-hour periods. The 0.3mg dose effectively elevated blood levels, decreased nocturnal motor function, and increased sleep onset. This before and after trial studied 13 children and compared their information to a 5-day baseline. Administration of melatonin lasted seven days. What is profoundly interesting is that many of these children were taking GABAergic medications, which are known to deplete melatonin, and AS children are thought to produce less melatonin than developmentally normal children, likely due to poorly formed pineal glands. That being said, these subjects likely have the most need for melatonin from an insufficiency perspective yet only 0.3mg was sufficient to see clinically relevant improvements.52 

Dr. Paolo Lissoni’s cancer research demonstrated that 20mg was effective in arresting tumor growth and improving quality of life markers.53,54 Studies since have all mirrored this dose; however, it is important to note that 20mg was a calculated dose. Little research to date has been conducted on lower doses to determine if they are as effective in cancer patients or if the physiological dose of 0.3mg can be used for prevention.

Hopefully, future studies will delve into these questions. In 2002 researcher Alfred J. Lewy and colleagues found that physiologic doses (0.5mg) may offer benefits that pharmacologic doses (20mg) do not.55 They observed the effects of dosage of melatonin in blind humans who often have disrupted circadian rhythms due to the pineal gland not receiving appropriate stimulation from the retina. They concluded that “too much melatonin may spill over onto the wrong zone of the melatonin phase-response curve”. The phase-response curve is the standard measure of biological rhythms. This supports the concept that too much melatonin may not be good for a person. It also begs the question, “How much is too much?”

It will be difficult to answer this for the masses as hormone production and timing of secretion has so many variables. In addition, bioavailability of the form or product used can play a part. Many practitioners swear by doses of 1-3 mg; however, they find that when they switch brands, lower doses are just as effective. Melatonin is quickly broken down by the body and should be dosed at the appropriate, personalized level for each patient. Because of this fast metabolism, melatonin must be used daily and not every second or third day. If a person feels best on 1mg of melatonin, 3mg of melatonin every third day is not appropriate. Products containing 3-5mg are often chosen because they are perceived as a good value but getting more medicine for your dollar is not always better if the dose is incorrect. For this reason, starting at the physiological dose of 0.3mg and increasing if necessary is often recommended except for specific conditions where higher doses are needed short-term such as jet lag, shift work, or cancer.

There are some general opinions on dosing melatonin from a timing perspective. Historically all research as it related to sleep administered melatonin 30-60 minutes prior to bed; however, some studies have shown that it can be taken up to 4 hours prior and be effective. Lewy suggests that dosing for sleep requires a minimum of twelve hours of wakefulness. Dosing for jet lag from eastbound travel includes a preflight early evening treatment of melatonin for 1-3 days leading up to travel, followed by treatment at bedtime for 4 days after arrival, most studies are on 3-5mg nightly. For westbound travel, melatonin can be used for 4 days at bedtime when in the new time zone. For difficulty falling asleep, melatonin can be taken 3-4 hours before an imposed sleep period over four weeks. However, as it is always recommended to take melatonin in conjunction with being in darkness versus light stimulation from television and computers, it is often more practical to adhere to the 30-60 minutes before bed.

For difficulty maintaining sleep, a short-term, high dose, repeated low doses, or a controlled-release formulation may be required depending on the cause of disrupted sleep maintenance. Some authorities suggest limiting melatonin to 0.3mg in children. The use of melatonin in children is now widely accepted for various disorders but since the studies range so widely in dosing, a critical analysis is required for each patient. One dose-dependent study found that using 0.05mg/kg was as effective as higher doses.56 Unfortunately, this was the lowest dose studied in this trial. In practical terms, this is 0.9 mg for a 40-pound child. Dysomnia, attention-deficit disorder, and autism spectrum disorder have been studied and reviewed, all confirming effectiveness and safety of melatonin. It should be noted that studies were of various lengths with some as short as two weeks and the longest lasting six months. Only one questionnaire-based study has looked at long-term melatonin use in children and by its design, was based on subjective symptom reports. In an average of 3.7 years of follow-up from previous clinical trial participation of pharmacologic doses of melatonin, 65% of children were still using melatonin as prescribed in the study but only 9% were able to discontinue use.57,58 Implications of this information are two-fold for the practicing clinician. 1) Most of the time, parents need to be prepared for lifelong melatonin use when giving pharmacologic doses and 2) because melatonin is over the counter, the dose initially recommended is what any given patient was on. Neither the parents nor children were being monitored in their melatonin use, but rather relied on the initial study proposal so dosing varied widely. Yet compliance nearly four years later was 65% due presumably to satisfaction of use.

Uses in seizure activity, idiopathic scoliosis, and anesthesia have been studied as well with positive outcomes. Where science has yet to meet clinical practice is dosing parameters may vary according to multiple factors such as the child’s medical problems, the severity and type of sleep problems, or the associated neurological pathology. Indiscriminate dosing may lead to unnecessary dependence. Finally, to underscore the discussion of dosing in both pediatrics and adults, it is important to understand that melatonin is metabolized via the liver almost exclusively by CYP1A2. Slow metabolism of this enzyme has clinical application. A melatonin clearance test is reasonable yet difficult to practically implement. Therefore, loss of response after several weeks may suggest a patient’s tolerance of melatonin and dose reduction. In one report, clinicians noted that “the initial good response to melatonin disappeared within a few weeks after starting treatment, while the good response returned only after considerable dose reduction.”

Medications

Melatonin should not be combined with certain medications such as blood pressure medications like methoxamine (Vasoxyl) and clonidine (Catopres), blood-thinning medications such as warfarin (Coumadin), MAO inhibitor drugs, steroids, and immunosuppressive medications. Additionally, women who are pregnant or nursing should not take melatonin without medical approval and/or supervision, and people with autoimmune conditions, diabetes, thyroid conditions, epilepsy, leukemia, lymphoproliferative disorders, or mood disorders should only take it under medical supervision.

SNH Medical Team

Tori Hudson

Naturopathic Doctor

Specializes in Women’s Health

Shawn Tassone MD, PhD, OBGYN
Specializes in Integrative Medicine

Henry Meissner PhD
Specializes in Nutritional Biochemistry

Mona Fahoum
Naturopthic Doctor
Specializes in Microbiome and Women’s Health

Jan Roberts

Pharmacist & Clinical Nutritionist

Specializes in Fertility and Preconception Health

Corey Schuler RN, DC and Certified Nutritionist Specialist

Specializes in Hormone and Metabolic Health

 References:

  1. Iguchi H, Kato K, Ibayashi H. Age-Dependent Reduction in Serum Melatonin Concentrations in Healthy Human Subjects. The Journal of Clinical Endocrinology &
    Metabolism. 1982;55(1):27-29. doi:10.1210/jcem-55-1-27
  2. Knutsson A. Health disorders of shift workers. Occup Med (Chic Ill). 2003;53(2):103-108. doi:10.1093/occmed/kqg048
  3. Zee P, Goldstein C. Treatment of Shift Work Disorder and Jet Lag. Curr Treat Options Neurol. 2010;12(5):396-411. doi:10.1007/s11940-010-0090-9
  4. Morgenthaler T, Lee-Chiong T, Alessi C et al. Practice Parameters for the Clinical Evaluation and Treatment of Circadian Rhythm Sleep Disorders. Sleep. 2007;30(11):1445-
    1459. doi:10.1093/sleep/30.11.1445
  5. Bhatti P, Mirick D, Randolph T et al. Oxidative DNA damage during sleep periods among nightshift workers. Occup Environ Med. 2016;73(8):537-544. doi:10.1136/
    oemed-2016-103629
  6. Ferracioli-Oda E, Qawasmi A, Bloch M. Meta-Analysis: Melatonin for the Treatment of Primary Sleep Disorders. PLoS ONE. 2013;8(5):e63773. doi:10.1371/journal.
    pone.0063773
  7. Auld F. et al. Evidence for the Efficacy of Melatonin in the Treatment of Primary Adult Sleep Disorders. Sleep Med Rev 2017;34:10-22)
  8. Escames G, Lopez A, Antonio Garcia J et al. The Role of Mitochondria in Brain Aging and the Effects of Melatonin. Curr Neuropharmacol. 2010;8(3):182-193.
    doi:10.2174/157015910792246245
  9. Jean-Louis G, Gizycki H, Zizi F. Melatonin effects on sleep, mood, and cognition in elderly with mild cognitive impairment. J Pineal Res. 1998;25(3):177-183. doi:10.1111/
    j.1600-079x.1998.tb00557.x
  10. Furio A, Brusco L, Cardinali D. Possible therapeutic value of melatonin in mild cognitive impairment: a retrospective study. J Pineal Res. 2007;43(4):404-409. doi:10.1111/
    j.1600-079x.2007.00491.x
  11. Tractenberg R, Singer C, Cummings J, Thal L. The Sleep Disorders Inventory: an instrument for studies of sleep disturbance in persons with Alzheimer's disease. J Sleep
    Res. 2003;12(4):331-337.doi:10.1046/j.0962-1105.2003.00374.x
  12. Esteban S, Garau C, Aparicio S et al. Chronic melatonin treatment and its precursor L-tryptophan improve the monoaminergic neurotransmission and related behavior in
    the aged rat brain. J Pineal Res. 2010;48(2):170-177. doi:10.1111/j.1600-079x.2009.00741.x
  13. Manda K, Reiter R. Melatonin maintains adult hippocampal neurogenesis and cognitive functions after irradiation. Prog Neurobiol. 2010;90(1):60-68. doi:10.1016/j.
    pneurobio.2009.10.019
  14. Olcese J, Cao C, Mori T et al. Protection against cognitive deficits and markers of neurodegeneration by long-term oral administration of melatonin in a transgenic model
    of Alzheimer disease. J Pineal Res. 2009;47(1):82-96. doi:10.1111/j.1600-079x.2009.00692.x
  15. Srinivasan V, Spence D, Pandi-Perumal S, Brown G, Cardinali D. Melatonin in Mitochondrial Dysfunction and Related Disorders. Int J Alzheimers Dis. 2011;2011:1-16.
    doi:10.4061/2011/326320
  16. J. Reiter R, C. Manchester L, Tan D. Neurotoxins: Free Radical Mechanisms and Melatonin Protection. Curr Neuropharmacol. 2010;8(3):194-210.
    doi:10.2174/157015910792246236
  17. Koziróg M, Poliwczak A, Duchnowicz P, Koter-Michalak M, Sikora J, Broncel M. Melatonin treatment improves blood pressure, lipid profile, and parameters of oxidative
    stress in patients with metabolic syndrome. J Pineal Res. 2010;50(3):261-266. doi:10.1111/j.1600-079x.2010.00835.x
  18. Simko F, Baka T, Paulis L, Reiter R. Elevated heart rate and nondipping heart rate as potential targets for melatonin: a review. J Pineal Res. 2016;61(2):127-137. doi:10.1111/
    jpi.12348
  19. Pandi-Perumal S, BaHammam A, Ojike N et al. Melatonin and Human Cardiovascular Disease. J Cardiovasc Pharmacol Ther. 2016;22(2):122-132.
    doi:10.1177/1074248416660622
  20. Nduhirabandi F, Maarman G. Melatonin in Heart Failure: A Promising Therapeutic Strategy? Molecules. 2018;23(7):1819. doi:10.3390/molecules23071819
  21. Aversa S, Pellegrino S, Barberi I, Reiter R, Gitto E. Potential utility of melatonin as an antioxidant during pregnancy and in the perinatal period. The Journal of Maternal-
    Fetal & Neonatal Medicine.
  22. Marseglia L, D’Angelo G, Manti S, Reiter R, Gitto E. Potential Utility of Melatonin in Preeclampsia, Intrauterine Fetal Growth Retardation, and Perinatal Asphyxia.
    Reproductive Sciences. 2015;23(8):970-977. doi:10.1177/1933719115612132
  23. Zeng K, Gao Y, Wan J et al. The reduction in circulating levels of melatonin may be associated with the development of preeclampsia. J Hum Hypertens. 2016;30(11):666-
    671. doi:10.1038/jhh.2016.37
  24. Tain Y, Lee C, Chan J, Hsu C. Maternal melatonin or N-acetylcysteine therapy regulates hydrogen sulfide-generating pathway and renal transcriptome to prevent prenatal
    NG-Nitro-L-arginine-methyl ester (L-NAME)-induced fetal programming of hypertension in adult male offspring. Am J Obstet Gynecol. 2016;215(5):636.e1-636.e72.
    doi:10.1016/j.ajog.2016.07.036
  25. Soleimani Rad S, Abbasalizadeh S, Ghorbani Haghjo A, Sadagheyani M, Montaseri A, Soleimani Rad J. Serum Levels of Melatonin and Oxidative Stress Markers and
    Correlation between Them in Infertile Men. J Caring Sci. 2013;2(4):287-94. doi:10.5681/jcs.2013.034
  26. Kratz E, Piwowar A, Zeman M, Stebelová K, Thalhammer T. Decreased melatonin levels and increased levels of advanced oxidation protein products in the seminal
    plasma are related to male infertility. Reproduction, Fertility and Development. 2016;28(4):507. doi:10.1071/rd14165
  27. Fernando S, Rombauts L. Melatonin: shedding light on infertility? - a review of the recent literature. J Ovarian Res. 2014;7(1):98. doi:10.1186/preaccept-1516771013137283
  28. Schwertner A, Conceição dos Santos C, Costa G et al. Efficacy of melatonin in the treatment of endometriosis: A phase II, randomized, double-blind, placebo-controlled
    trial. Pain. 2013;154(6):874-881. doi:10.1016/j.pain.2013.02.025
  29. ArushanyanArushanian É, Karakov K, Él'bek'ian K. Therapeutic potential of melatonin in oral cavity diseases. Eksp Klin Farmakol. 2012;75(6):48-52.
  30. Cengiz M, Cengiz S, Wang H. Melatonin and Oral Cavity. Int J Dent. 2012;2012:1-9. doi:10.1155/2012/491872
  31. Celinski K, Konturek P, Konturek S et al. Effects of melatonin and tryptophan on healing of gastric and duodenal ulcers with Helicobacter pylori infection in humans. J Physiol Pharmacol. 2011;62(5):521-6.(5):521-6.
  32. Mozaffari S, Abdollahi M. Melatonin, a Promising Supplement in Inflammatory Bowel Disease: A Comprehensive Review of Evidences. Curr Pharm Des. 2011;17(38):4372- 4378. doi:10.2174/138161211798999357
  33. Kandil T, Mousa A, El-Gendy A, Abbas A. The potential therapeutic effect of melatonin in gastro-esophageal reflux disease. BMC Gastroenterol. 2010;10(1). doi:10.1186/1471-230x-10-7
  34. Paulose J, Cassone V. The melatonin-sensitive circadian clock of the enteric bacterium Enterobacter aerogenes. Gut Microbes. 2016;7(5):424-427. doi:10.1080/19490976. 2016.1208892
  35. Ochoa J, Díaz-Castro J, Kajarabille N et al. Melatonin supplementation ameliorates oxidative stress and inflammatory signaling induced by strenuous exercise in adult human males. J Pineal Res. 2011;51(4):373-380. doi:10.1111/j.1600-079x.2011.00899.x
  36. Negi G, Kumar A, Sharma S. Melatonin modulates neuroinflammation and oxidative stress in experimental diabetic neuropathy: effects on NF-KB and Nrf2 cascades. J Pineal Res. 2010;50(2):124-31. doi:10.1111/j.1600-079x.2010.00821.x
  37. Gonçalves A, Martini Ferreira A, Ribeiro R, Zukerman E, Cipolla-Neto J, Peres M. Randomised clinical trial comparing melatonin 3 mg, amitriptyline 25 mg and placebo for migraine prevention. Journal of Neurology, Neurosurgery & Psychiatry. 2016;87(10):1127-1132. doi:10.1136/jnnp-2016-313458
  38. Gelfand A, Goadsby P. The Role of Melatonin in the Treatment of Primary Headache Disorders. Headache: The Journal of Head and Face Pain. 2016;56(8):1257-1266. doi:10.1111/head.12862
  39. Hurtuk A, Dome C, Holloman C et al. Melatonin: Can it Stop the Ringing? Annals of Otology, Rhinology & Laryngology. 2011;120(7):433-440. doi:10.1177/000348941112000703
  40. Chaste P, Clement N, Botros H et al. Genetic variations of the melatonin pathway in patients with attention-deficit and hyperactivity disorders. J Pineal Res. 2011;51(4):394- 399. doi:10.1111/j.1600-079x.2011.00902.x
  41. Melke J, Goubran Botros H, Chaste P et al. Abnormal melatonin synthesis in autism spectrum disorders. Mol Psychiatry. 2008;13(1):90-98. doi:10.1038/sj.mp.4002016
  42. Rossignol D, Frye R. Melatonin in autism spectrum disorders: a systematic review and meta-analysis. Developmental Medicine & Child Neurology. 2011;53(9):783-792. doi:10.1111/j.1469-8749.2011.03980.x
  43. Lissoni P, Barni S, Cattaneo G et al. Clinical Results with the Pineal Hormone Melatonin in Advanced Cancer Resistant to Standard Antitumor Therapies. Oncology. 1991;48(6):448-450.doi:10.1159/000226978
  44. Farez M, Mascanfroni I, Méndez-Huergo S et al. Melatonin Contributes to the Seasonality of Multiple Sclerosis Relapses. Cell. 2015;162(6):1338-1352. doi:10.1016/j. cell.2015.08.025
  45. Agorastos A, Huber C. The role of melatonin in glaucoma: implications concerning pathophysiological relevance and therapeutic potential. J Pineal Res. 2011;50(1):1-7. doi:10.1111/j.1600-079x.2010.00816.x6
  46. Rastmanesh R. Potential of melatonin to treat or prevent age-related macular degeneration through stimulation of telomerase activity. Med Hypotheses. 2011;76(1):79-85. doi:10.1016/j.Mehy.2010.08.036
  47. Srinivasan V, Spence D, Pandi-Perumal S, Trakht I, Cardinali D. Jet lag: Therapeutic use of melatonin and possible application of melatonin analogs. Travel Med Infect Dis. 2008;6(1-2):17-28.doi:10.1016/j.tmaid.2007.12.002
  48. Herxheimer A, Petrie K. Melatonin for the prevention and treatment of jet lag. Cochrane Database of Systematic Reviews. 2002;(2):CD001520. doi:10.1002/14651858. cd001520
  49. Melatonin-micronutrients Osteopenia Treatment Study (MOTS). Aging 2017 Jan; 9(1): 256–285.
  50. (ref: Kotlarczyk MP, Lassila HC, O'Neil CK, D'Amico F, Enderby LT, Witt-Enderby PA, Balk JL. Melatonin osteoporosis prevention study (MOPS): a randomized, double blind, placebo-controlled study examining the effects of melatonin on bone health and quality of life in perimenopausal women. J Pineal Res. 2012;52:414–26).
  51. Amstrup AK, Sikjaer T, Heickendorff L, Mosekilde L, Rejnmark L. Melatonin improves bone mineral density at the femoral neck in postmenopausal women with osteopenia: a randomized controlled trial. J Pineal Res. 2015;59:221–29.
  52. Zhdanova I, Wurtman R, Wagstaff J. Effects of a Low Dose of Melatonin on Sleep in Children with Angelman Syndrome. Journal of Pediatric Endocrinology and Metabolism. 1999;12(1):57-67.doi:10.1515/jpem.1999.12.1.57
  53. Lissoni P. Is there a role for melatonin in supportive care? Supportive Care in Cancer. 2002;10(2):110-116. doi:10.1007/s005200100281 54. Kaczor T. An Overview of Melatonin and Breast Cancer. Natural Medicine Journal. 2010;2(2).
  54. Lewy A, Emens J, Sack R, Hasler B, Bernert R. Low, but not high, doses of melatonin entrained a free-running blind person with a long circadian period. Chronobiol Int. 2002;19(3):649-658.doi:10.1081/cbi-120004546
  55. Sack R, Auckley D, Auger R et al. Circadian Rhythm Sleep Disorders: Part II, Advanced Sleep Phase Disorder, Delayed Sleep Phase Disorder, Free-Running Disorder, and Irregular Sleep-Wake Rhythm. Sleep. 2007;30(11):1484-1501. doi:10.1093/sleep/30.11.1484
  56. Hoebert M, van der Heijden K, van Geijlswijk I, Smits M. Long-term follow-up of melatonin treatment in children with ADHD and chronic sleep onset insomnia. J Pineal Res. 2009;47(1):1-7. doi:10.1111/j.1600-079x.2009.00681.x
  57. Vural E, van Munster B, de Rooij S. Optimal Dosages for Melatonin Supplementation Therapy in Older Adults: A Systematic Review of Current Literature. Drugs Aging. 2014;31(6):441-451. doi:10.1007/s40266-014-0178-0